Login
Israel-Hamas Conflict
Motorsports
Social Media
Natural Disasters
Floods
World Cup
Artificial Intelligence
Education
BRICS
Independence Day
Wrestling
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Summary by pharmtech.com
The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

1 Articles

All
Left
Center
1
Right
pharmtech.compharmtech.com
Center

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmtech.com broke the news in on Thursday, June 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal